2641
Hypertension and the combination of bevacizumab / irinotecan may be additional risk factors for CIN development .
 Disease: Hypertension; Chemical: bevacizumab; Chemical: irinotecan
Please list all entity words in the text that fit the category.Output format is "type1: word1; type2: word2". 
Option: Disease, Chemical 
Text: {0} 
Answer:
 Disease: Hypertension; Chemical: bevacizumab; Chemical: irinotecan